Production (Stage)
Galmed Pharmaceuticals Ltd.
GLMD
$1.68
$0.085.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 630.00K | 572.00K | 688.00K | 688.00K | 766.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.26M | 1.64M | 1.22M | 1.22M | 1.40M |
| Operating Income | -1.26M | -1.64M | -1.22M | -1.22M | -1.40M |
| Income Before Tax | -1.10M | -3.21M | -1.12M | -1.12M | -1.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.10M | -3.21M | -1.12M | -1.12M | -1.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.10M | -3.21M | -1.12M | -1.12M | -1.28M |
| EBIT | -1.26M | -1.64M | -1.22M | -1.22M | -1.40M |
| EBITDA | -1.24M | -1.64M | -1.15M | -1.15M | -1.39M |
| EPS Basic | -0.62 | -2.00 | -2.13 | -2.13 | -2.10 |
| Normalized Basic EPS | -0.39 | -0.80 | -1.33 | -1.33 | -1.31 |
| EPS Diluted | -0.62 | -2.00 | -2.13 | -2.13 | -2.10 |
| Normalized Diluted EPS | -0.39 | -0.80 | -1.33 | -1.33 | -1.31 |
| Average Basic Shares Outstanding | 1.78M | 1.61M | 524.60K | 524.60K | 608.40K |
| Average Diluted Shares Outstanding | 1.78M | 1.61M | 524.60K | 524.60K | 608.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |